[1] Siegel RL, Miller KD, Jemal A.  Cancer statistics, 2020[J]. CA: Cancer J Clin, 2020, 70(1): 7-30.   doi: 10.3322/caac.21590
[2] 许莉, 李素平.  18F-FDG PET/CT代谢参数与非小细胞肺癌EGFR、ALK、KRAS突变的相关性研究进展[J]. 国际放射医学核医学杂志, 2020, 44(8): 515-521.   doi: 10.3760/cma.j.cn121381-201906035-00066
Xu L, Li SP.  Research progress on the correlation between 18F-FDG PET/CT metabolic parameters and mutations of EGFR, ALK and KRAS in non-small cell lung cancer[J]. Int J Radiat Med Nucl Med, 2020, 44(8): 515-521.   doi: 10.3760/cma.j.cn121381-201906035-00066
[3] Kandathil A, Kay FU, Butt YM, et al.  Role of FDG PET/CT in the eighth edition of TNM staging of non-small cell lung cancer[J]. Radiographics, 2018, 38(7): 2134-2149.   doi: 10.1148/rg.2018180060
[4] 林小敏, 潘雪艳, 唐明灯.  18F-FDG PET/CT 显像在直肠癌术前分期中的价值及与临床病理特征关系的研究[J]. 国际放射医学核医学杂志, 2020, 44(10): 641-648.   doi: 10.3760/cma.j.cn121381-201909027-00089
Lin XM, Pan XY, Tang MD.  Preoperative staging of rectal cancer with 18F-FDG PET/CT and its relationship with clinicopathological features[J]. Int J Radiat Med Nucl Med, 2020, 44(10): 641-648.   doi: 10.3760/cma.j.cn121381-201909027-00089
[5] Sivrikoz CM, Ak I, Simsek FS, et al.  Is mediastinoscopy still the gold standard to evaluate mediastinal lymph nodes in patients with non-small cell lung carcinoma?[J]. Thorac Cardiovasc Surg, 2012, 60(2): 116-121.   doi: 10.1055/s-0030-1271148
[6]

Schmidt-Hansen M, Baldwin DR, Hasler E, et al. PET-CT for assessing mediastinal lymph node involvement in patients with suspected resectable non-small cell lung cancer[J/OL]. Cochrane Database Syst Rev, 2014, 2014(11): CD009519[2021-05-26]. https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD009519.pub2/full. DOI: 10.1002/14651858.CD009519.pub2.
[7] Ohno Y, Fujisawa Y, Sugihara N, et al.  Dynamic contrast-enhanced perfusion area-detector CT: preliminary comparison of diagnostic performance for N stage assessment with FDG PET/CT in non-small cell lung cancer[J]. AJR Am J Roentgenol, 2017, 209(5): W253-W262.   doi: 10.2214/AJR.17.17959
[8] Gao XL, Wang SS, Cao DB, et al.  The role of plasma D-dimer levels for predicting lymph node and mediastinal lymph node involvement in non-small cell lung cancer[J]. Clin Respir J, 2018, 12(6): 2151-2156.   doi: 10.1111/crj.12786
[9] Rami-Porta R, Bolejack V, Crowley J, et al.  The IASLC lung cancer staging project: proposals for the revisions of the T descriptors in the forthcoming eighth edition of the TNM classification for lung cancer[J]. J Thorac Oncol, 2015, 10(7): 990-1003.   doi: 10.1097/JTO.0000000000000559
[10]

中国临床肿瘤学会指南工作委员会. 中国临床肿瘤学会(CSCO)非小细胞肺癌诊疗指南-2020[M]. 北京: 人民卫生出版社, 2020.

Guidelines Working Committee of Chinese Society of Clinical Oncology. Guidelines of Chinese Society of Clinical Oncology (CSCO): non-small cell lung cancer-2020[M]. Beijing: People's Medical Publishing House, 2020.
[11] Pahk K, Chung JH, Yi E, et al.  Metabolic tumor heterogeneity analysis by F-18 FDG PET/CT predicts mediastinal lymph node metastasis in non-small cell lung cancer patients with clinically suspected N2[J]. Eur J Radiol, 2018, 106: 145-149.   doi: 10.1016/j.ejrad.2018.07.028
[12] Budiawan H, Cheon GJ, Im HJ, et al.  Heterogeneity analysis of 18F-FDG uptake in differentiating between metastatic and inflammatory lymph nodes in adenocarcinoma of the lung: comparison with other parameters and its application in a clinical setting[J]. Nucl Med Mol Imaging, 2013, 47(4): 232-241.   doi: 10.1007/s13139-013-0216-6
[13]

Fortuny MS, Gallego M, Berna L, et al. FDG-PET parameters predicting mediastinal malignancy in lung cancer[J/OL]. BMC Pulm Med, 2016, 16: 177[2021-05-26]. https://link.springer.com/article/10.1186/s12890-016-0338-6. DOI: 10.1186/s12890-016-0338-6.
[14] Park SY, Yoon JK, Park KJ, et al.  Prediction of occult lymph node metastasis using volume-based PET parameters in small-sized peripheral non-small cell lung cancer[J]. Cancer Imaging, 2015, 15: 21-.   doi: 10.1186/s40644-015-0058-9
[15] Moloney F, Ryan D, McCarthy L, et al.  Increasing the accuracy of 18F-FDG PET/CT interpretation of "mildly positive" mediastinal nodes in the staging of non-small cell lung cancer[J]. Eur J Radiol, 2014, 83(5): 843-847.   doi: 10.1016/j.ejrad.2014.01.016
[16] Shinya T, Rai K, Okumura Y, et al.  Dual-time-point F-18 FDG PET/CT for evaluation of intrathoracic lymph nodes in patients with non-small cell lung cancer[J]. Clin Nucl Med, 2009, 34(4): 216-221.   doi: 10.1097/RLU.0b013e31819a1f3d
[17]

Simsek FS, Comak A, Asik M, et al. Is FDG-PET/CT used correctly in the combined approach for nodal staging in NSCLC patients?[J/OL]. Niger J Clin Pract, 2020, 23(6): 842−847[2021-05-26]. https://www.njcponline.com/article.asp?issn=1119-3077;year=2020;volume=23;issue=6;spage=842;epage=847;aulast=Simsek. DOI: 10.4103/njcp.njcp_2_19.